Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge

NCT03698695 is registered in ClinicalTrials.gov with Theranexus as lead sponsor.

NCT NCT03698695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03698695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge
Lead sponsor
Theranexus
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2018
Completion date
December 20, 2019
Enrollment
152 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, cognitive impairment